Methods and compositions for treating stroke
Some embodiments include methods of treating, inhibiting, or ameliorating ischemic stroke or a symptom thereof in a subject. Some embodiments include oxygenated fluid for use in treating, inhibiting, or ameliorating ischemic stroke. The oxygenated fluid may comprise charge-stabilized oxygen-containing nanostructures.
1. A method of treating, inhibiting, or ameliorating ischemic stroke or a symptom thereof in a subject, the method comprising:
identifying the subject as suffering from, or likely to be suffering from an ischemic stroke or a symptom thereof, and
administering an oxygenated fluid comprising charge stabilized oxygen-containing nanostructures to the subject intravenously at a rate of about 1 to 2 cc/kg/hr for a duration of at least 10 hours.
2. The method of claim 1 , wherein the oxygenated fluid is a pharmaceutical saline solution comprising charge-stabilized oxygen-containing nanostructures, a majority of the nanostructures having a diameter of less than 100 nanometers, wherein the pharmaceutical saline solution comprised at least 20 ppm oxygen at the time it was manufactured.
3. The method of claim 2 , wherein the nanostructures comprise nanobubbles, a majority of the nanobubbles having a diameter of less than 100 nanometers.
4. The method of claim 1 , wherein the oxygenated fluid is administered for at least 48 hours.
5. The method of claim 1 , wherein the oxygenated fluid is administered in two or more discrete events, separated by time periods of non-administration.
6. The method of claim 1 , wherein the oxygenated fluid comprises at least 40 ppm oxygen at standard temperature and pressure.
7. The method of claim 1 , wherein the oxygenated fluid comprises saline.
8. The method of claim 1 , wherein the oxygenated fluid does not comprise blood or perfluorocarbon.
9. The method of claim 1 , wherein the oxygenated fluid is oxygenated by dissolved oxygen.
10. The method of claim 1 , wherein at least 50% of the oxygenation in the oxygenated fluid comprises dissolved oxygen.
11. The method of claim 1 , wherein the oxygen in the oxygenated fluid has been present in an amount of at least 15 ppm at standard temperature and pressure for at least 3 hours.
12. The method of claim 1 , wherein the oxygen in the oxygenated fluid comprises modified or charged oxygen species.
13. The method of claim 1 , wherein the oxygenated fluid comprises no more than trace amounts of ozone.
14. The method of claim 1 , further comprising administering an additional therapeutic agent to the subject.
15. The method of claim 1 , wherein said administering comprises delivering the oxygen of the oxygenated fluid to brain cells of the subject, wherein said brain cells were subjected to ischemia followed by reperfusion.
16. The method of claim 1 , wherein the administered oxygenated fluid is effective to inhibit hypoxia of brain cells, inhibit reperfusion damage to brain cells, or inhibit a decline in a behavior following the ischemic stroke, or any combination thereof, of the subject.
17. The method of claim 16 , wherein the behavior is selected from the group consisting of: consciousness, defense reaction, grasp reflex, extremity movement, gait, circling, bradykinesia, balance, neglect, visual field cut/hemianopsia or facial weakness, or a combination of two or more of any of the listed items.